Full Text
The Full Text of this article is available as a PDF (65.6 KB).
Figure 1 .
Retrospective health economic analysis of CIBIS I (France): mean cost per patient (US$1 = FF5).
Figure 2 .
MEMO study: ratio of inpatient versus outpatient care after hospital admission.9
Figure 3 .
Retrospective health economic analysis of CIBIS (UK). US$1 = £0.63
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Delea T. E., Vera-Llonch M., Richner R. E., Fowler M. B., Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999 Mar 15;83(6):890–896. doi: 10.1016/s0002-9149(98)01066-2. [DOI] [PubMed] [Google Scholar]
- Kupersmith J., Holmes-Rovner M., Hogan A., Rovner D., Gardiner J. Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Prog Cardiovasc Dis. 1995 Jan-Feb;37(4):243–271. doi: 10.1016/s0033-0620(05)80009-x. [DOI] [PubMed] [Google Scholar]
- Levy P., Lechat P., Leizorovicz A., Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther. 1998 Jul;12(3):301–305. doi: 10.1023/a:1007773901631. [DOI] [PubMed] [Google Scholar]
- McMurray J., Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics. 1996 Mar;9(3):188–197. doi: 10.2165/00019053-199609030-00002. [DOI] [PubMed] [Google Scholar]
- Schädlich P. K., Paschen B., Brecht J. G. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics. 1998 Jan;13(1 Pt 2):147–155. doi: 10.2165/00019053-199813010-00014. [DOI] [PubMed] [Google Scholar]
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9–13. [PubMed] [Google Scholar]